Fresh Tracks Therapeutics (DB:VCC) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

VCC Stoklara Genel Bakış

Does not have significant operations.

VCC temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Risk Analizi

Hisse senetleri oldukça likit değildir

Kazançlar son 5 yılda yılda 5.8% oranında azaldı

Anlamlı bir piyasa değeri yok ( €5M )

Fresh Tracks Therapeutics, Inc. Rakipler

co.don

XTRA:CNW

€6.5m

2invest

XTRA:2INV

€60.4m

Sangui Biotech International

HMSE:SBH

€419.8k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Fresh Tracks Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.73
52 Haftanın En Yüksek Seviyesi	US$0.96
52 Haftanın En Düşük Seviyesi	US$0.44
Beta	0.49
11 Aylık Değişim	0%
3 Aylık Değişim	-1.48%
1 Yıllık Değişim	5.04%
33 Yıllık Değişim	-98.45%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-99.56%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	VCC	DE Biotechs	DE Pazar
7D	0%	1.7%	1.8%
1Y	5.0%	-15.1%	13.8%

Getiri vs. Endüstri: VCC geçen yıl % -15.1 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: VCC geçen yıl % 13.8 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is VCC's price volatile compared to industry and market?
VCC volatility
VCC Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.1%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: VCC son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: VCC 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	13	Bert Marchio	ir.frtx.com

Fresh Tracks Therapeutics, Inc. Temel Bilgiler Özeti

Fresh Tracks Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
VCC temel i̇stati̇sti̇kler
Piyasa değeri	€4.95m
Kazançlar(TTM)	-€5.24m
Gelir(TTM)	€7.37m

0.7x

P/S Oranı

-0.9x

F/K Oranı

VCC aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
VCC gelir tablosu (TTM)
Gelir	US$8.01m
Gelir Maliyeti	US$3.18m
Brüt Kâr	US$4.82m
Diğer Giderler	US$10.52m
Kazançlar	-US$5.69m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.95
Brüt Marj	60.25%
Net Kâr Marjı	-71.12%
Borç/Özkaynak Oranı	0%

VCC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

VCC Stoklara Genel Bakış

Ödüller

Risk Analizi

Fresh Tracks Therapeutics, Inc. Rakipler

XTRA:CNW

€6.5m

XTRA:2INV

€60.4m

HMSE:SBH

€419.8k

BST:BPXA

€772.4k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Recent updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

New minor risk - Revenue size

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02

Third quarter 2022 earnings released: US$2.07 loss per share (vs US$7.15 loss in 3Q 2021)

Insufficient new directors

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02

Insufficient new directors

Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements

Second quarter 2022 earnings released: US$0.01 loss per share (vs US$7.29 loss in 2Q 2021)

Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Brickell Biotech, Inc. Announces Executive Changes

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.15 loss in 1Q 2021)

Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020)

Co-Founder & Chairman of the Board recently bought €113k worth of stock

Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market

Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020)

Forecast to breakeven in 2025

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

CEO & Director recently bought €99k worth of stock

Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021

Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019)

Revenue misses expectations

Brickell Biotech, Inc. to Report Q4, 2020 Results on Mar 09, 2021

New 90-day high: €1.36

Brickell Biotech, Inc. Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (Ecclock®)

New 90-day high: €0.90

Brickell Biotech, Inc. Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study

Brickell Biotech, Inc. Announces Management Changes

Third quarter 2020 earnings released: US$0.15 loss per share

Brickell Biotech, Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day high: €0.91

Brickell Biotech, Inc. Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis

New 90-day low - €0.65

New 90-day low - €0.67